Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Regeneron Pharmaceuticals Q1 2024 earnings: EPS down 5%, sales miss; Eylea US sales drop 16%, Dupixent offsets. Oncology treatm...
New real-world evidence shows Beyfortus (nirsevimab) substantially reduced RSV lower respiratory tract disease and hospitaliz...
With the earnings season now halfway through, the percentage of S&P 500 companies reporting positive earnings surprises and...
Sobi® today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued a p...
AbbVie's Upadacitinib outperforms dupilumab in Phase 3b/4 study for atopic dermatitis treatment, achieving superior efficac...
Sanofi reports Q1 operating income at 2.8 billion euros, down 14.7%. Beat consensus EPS at $0.97. Sales reach $11.36 billion, l...
The back-and-forth motion in the market continues, with the index futures pointing to a lower opening on Thursday. Meta Platfor...
Business EPS guidance reiterated Sanofi expects 2024 business EPS(1) to remain roughly stable excluding the impact of an expec...
